MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
NovaBay Pharmaceuticals Cash Conversion Cycle 2011-2026 | NBY
Annual Cash Conversion Cycle NovaBay Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 116 | 150 | 123 | 68.8 | 92.8 | 36.1 | 79.4 | 132 | -285 | -915 | -3.17 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 150 | -3.17 K | -325 |
Quarterly Cash Conversion Cycle NovaBay Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -64.8 | - | - | - | -1.26 | -31.5 | -18.9 | - | 263 | 123 | 309 | - | 184 | 119 | 127 | - | 5.71 | 36.5 | 32.4 | - | 52.1 | 13.7 | 36.7 | - | 36.6 | 36.5 | -14.7 | - | -74.5 | -51.6 | -42.4 | - | 6.65 | 4.97 | 35.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 309 | -74.5 | 44.9 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K |  USA |
 |
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 319.85 | -4.06 % | $ 41.9 B | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
205 | $ 21.82 | 0.65 % | $ 1.02 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
-1.83 K | - | -5.16 % | $ 5.39 M | USA |
 |
Akebia Therapeutics
AKBA
|
42 | $ 1.37 | -11.94 % | $ 352 M | USA |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.28 | 0.94 % | $ 458 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 24.04 | -2.2 % | $ 3.06 B | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.59 | 6.81 % | $ 423 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | USA |
 |
Clearside Biomedical
CLSD
|
-1.67 K | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
-3.74 K | $ 33.68 | -0.56 % | $ 2.24 B | USA |
 |
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | USA |